Don’t emulate NZ PBS model: experts

DOCTORS, consumers and pharmaceutical bodies are warning that Australia could follow New Zealand's path to "one of the worst access rates to medicines in the industrialised world" if Cabinet continues to defer PBS listings for medicines, contrary to recommendations by the Pharmaceutical Benefits Advisory Committee (PBAC).

Medicines Australia CEO Dr Brendan Shaw (PhD) said the New Zealand government's "cost-focused" approach to providing medicines on their pharmaceutical schedule had forced the industry to reduce research and investment